Article Information
History
- January 21, 2022.
Article Versions
- You are currently viewing Version 1 of this article (January 21, 2022 - 22:48).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Nancy H. L. Leung*,1,2,
- Samuel M. S. Cheng1,
- Mario Martín-Sánchez1,
- Niki Y. M. Au1,
- Yvonne Y. Ng1,
- Leo L. H. Luk1,
- Karl C. K. Chan1,
- John K. C. Li1,
- Yonna W. Y. Leung1,
- Leo C. H. Tsang1,
- Sara Chaothai1,
- Kelvin K. H. Kwan1,
- Dennis K. M. Ip1,
- Leo L. M. Poon1,3,4,
- Gabriel M. Leung1,2,
- J. S. Malik Peiris†,1,3,4 and
- Benjamin J. Cowling*,†,1,2
- 1WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong; Hong Kong Special Administrative Region, China
- 2Laboratory of Data Discovery for Health; Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, China
- 3HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong; Hong Kong Special Administrative Region, China
- 4Centre for Immunology and Infection; Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, China
- ↵*Corresponding authors: bcowling{at}hku.hk and nanleung{at}connect.hku.hk
↵† Joint senior authors with equal contribution
Posted January 21, 2022.
BNT162b2 vaccine boosts neutralizing antibodies to ancestral SARS-CoV-2 & Omicron variant in adults received 2-dose inactivated vaccine
